Real-world cell-free circulating tumor DNA (ctDNA) analysis identifies CDK4/6 inhibitor resistance and tumor evolution in HR+ advanced breast cancer - PubMed
6 hours ago
- #CDK4/6 inhibitors
- #ctDNA
- #breast cancer resistance
- Real-world ctDNA analysis identifies CDK4/6 inhibitor resistance and tumor evolution in HR+ advanced breast cancer.
- ESR1 and RB1 alterations increased post-CDK4/6i treatment, indicating resistance mechanisms.
- Presence of CDK4/6i+ET-R mutations before treatment correlates with worse outcomes in time on therapy and overall survival.
- The study suggests potential for using resistance signatures to personalize treatment selection in clinical practice.
- Further research is needed to explore the findings and their applications.